DiaSorin offers the growth line, on the RIA format and LIAISON® systems.
The LIAISON® hGH assay uses chemiluminescent immunoassay (CLIA) technology for the in vitro quantitative determination of human growth hormone in human serum specimens. The test has to be performed on the LIAISON® Analyzer.
In vitro assay for the quantitative determination of IGF-I (Insulin-like Growth Factor I) in human serum. The test has to be performed on the LIAISON® Analyzer.
Together with the nervous system, the endocrine system regulates and integrates the body’s metabolic activities. The endocrine system meets the nervous system at the hypothalamus. The hypothalamus controls the function of the endocrine organs by neural and hormonal pathways. In response to the hypothalamus, the anterior pituitary secretes prolactin, which stimulates milk production and human Growth Hormone (hGH) which affects most body tissues.
hGH stimulates growth by increasing protein synthesis, fat mobilization and by decreasing carbohydrate utilization. Hypo secretion of hGH results in dwarfism; hyper secretion causes gigantism and acromegaly in adults.
IGF-I or Sometomedin-C is a peptide highly dependent on growth hormone and has a potent growth promoting activity. The IGF-I is transported in serum by several IGF-binding proteins. Measurements of IGF-I are useful adjunt to assessment of growth hormone secretion. A normal plasma or serum IGF-I concentration is strong evidence against GH deficiency, with the exception of GH deficient children with craniopharyngiomas and adults who have prolactin secreting tumor accompanied with GH deficiency and prolactin excess.
One of the most important binding proteins is the IGFBP-3. This protein is responsible for the maintenance of appropriate levels of IGF-I in serum, minimising concentration fluctuations. IGFBP-3 levels increase in GH deficient patient after GH administration and it is useful in assessing nutritional status, since it decreases during both caloric and protein restriction.